Double blind-randomized controlled trial for the efficacy of third line H. pylori eradication therapy between refabutin-including 10 days and 14 days regime
Phase 3
- Conditions
- H. pylori-positve patients after the 2nd line eradication failure
- Registration Number
- JPRN-UMIN000011963
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 170
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with allergy for rifamycins 2. Patients with past histry of tuberculosis or nontuberculous mycobacterial infection 3. Patients with allergy for PPIs 4. Patients with allergy for penicillin 5. Patients with severe liver injury and/or severe renal damage 6. Pregnancy or possible pregnancy 7. Patients who are taking voriconazole 8. Patients with uveitis 9. Patients who were recognized as inappropriate for entry
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The efficacy of H. pylori eradication
- Secondary Outcome Measures
Name Time Method